Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of GB-0706 for heparin resistance during cardiopulmonary bypass surgery
jRCT2031230269Phase 3Completed
- Sponsor
- Japan Blood Products Organization
- Start
- Oct 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of antithrombin III in heparin resistance, sponsored by Japan Blood Products Organization. Primary endpoint: Primary efficacy endpoint. Started Oct 2023; status: completed.
02
Drugs
antithrombin III
03
Conditions
heparin resistance
Beyond the preview
Go deeper on jRCT2031230269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230269.